⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Cdymax (India) Pharma Private Limited and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Cdymax (India) Pharma Private Limited
↗Bangalore, India
Cdymax (India) Pharma Private Limited is an Indian pharmaceutical manufacturer specializing in the production of Active Pharmaceutical Ingredients (APIs), with a strong focus on oncology and general therapeutic areas. Founded in 1994 (originally as Intermed Pharma), the company operates manufacturing facilities in Jigani, Bangalore, and has established itself as a supplier of APIs for both human and veterinary use.
The company has undergone significant evolution, including a name change in 2009 and an investment from Couplet Limited in 2006. It maintains infrastructure for both oncology and general API production, with significant annual capacity, and is currently navigating regulatory scrutiny following recent FDA inspection findings.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$12M-$60M
Founded:1994
Ownership:private
Status:operating
FUNDING
Investors:Couplet Limited
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (API manufacturing)
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Manorama Avinash - Executive Director
Santosh Datta Naik - Director
Board Members:Manorama Avinash, Santosh Datta Naik
LINKS
Website:cdymax.in
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Cdymax (India) Pharma Private Limited. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.